Evidence map›Paper›PMID 39312235›Full record

ArticleJAMA network open2024

Alzheimer Dementia Among Individuals With Down Syndrome.

Eric Rubenstein, Salina Tewolde, Amy Michals, Jennifer Weuve, Juan Fortea, Matthew P Fox, Marcia Pescador Jimenez, Ashley Scott, Yorghos Tripodis, Brian G Skotko

Registry-linked trialAbstract read
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07531940 (Phase 1B Trial on Escalating Doses of Memantine in Down Syndrome), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07531940 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Phase 1B Trial on Escalating Doses of Memantine in Down Syndrome

TypeinterventionalSponsorUniversity Hospitals Cleveland Medical CenterRan2026 to 2028Enrolled25ConditionsDown Syndrome, Intellectual DisabilityArmsMemantine
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Technology-natives and technology-adopters: Age differences in remote cognitive assessment in Alzheimer disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Age predicts Alzheimer's in Down syndrome better than MRI, plasma, or cognition.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  10. Review
  11. Immediate and Underlying Causes of Death and Survival Rates in Aging Adults With Down Syndrome.Journal of applied research in intellectual disabilities : JARID · 2026
    Article
  12. System changes to empower primary care in Alzheimer's disease detection and care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  13. Factors impacting survival in individuals with Down syndrome-associated Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Anticholinergics, executive function, and cognitive/behavioral changes in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eric RubensteinBoston University School of Public Health, Boston, Massachusetts.
Salina TewoldeBoston University School of Public Health, Boston, Massachusetts.
Amy MichalsBoston University School of Public Health, Boston, Massachusetts.
Jennifer WeuveBoston University School of Public Health, Boston, Massachusetts.
Juan ForteaSant Pau Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Spain.
Matthew P FoxBoston University School of Public Health, Boston, Massachusetts.
Marcia Pescador JimenezBoston University School of Public Health, Boston, Massachusetts.
Ashley ScottBoston University School of Public Health, Boston, Massachusetts.
Yorghos TripodisBoston University School of Public Health, Boston, Massachusetts.
Brian G SkotkoMassachusetts General Hospital, Boston.

Funding

The Role of Inflammation and NGF Dysfunction in the Evolution of Alzheimer Disease Pathology in Down Syndrome-RevisionRF1AG056850 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI BUSCIGLIO, JORGE A, CUELLO, A CLAUDIO · 2018 to 2020
$5.9M
Down Syndrome Toward Optimal Trajectories and Health using Medicaid Analytic eXtract (DS-TO-THE-MAX)R01AG073179 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Eric S Rubenstein · 2021 to 2026
$3.5M
Neurodegenerative diseases and the role of green space: A deep learning assessmentR00AG066949 · NIA · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI PESCADOR JIMENEZ, MARCIA IXCHEL · 2022 to 2024
$738k
Biological Correlates of Alzheimer in Down Syndrome.R21AG056974 · NIA · UNIVERSITY OF DENVER (COLORADO SEMINARY) · PI GRANHOLM-BENTLEY, ANN-CHARLOTTE ESTHER · 2017 to 2018
$414k
NIA NIH HHS R00 AG066949NIA NIH HHS R01 AG073179NIA NIH HHS R21 AG056974NIA NIH HHS RF1 AG056850
6 · The paper itself

Abstract

Importance: With the advancement in administrative data as a research tool and the reliance on public health insurance for individuals with Down syndrome, population-level trends in Alzheimer dementia in this population are beginning to be understood. Objective: To comprehensively describe the epidemiology of Alzheimer dementia in adults with Down syndrome in a full US Medicare and Medicaid sample. Design, Setting, and Participants: This cohort study included 132 720 adults aged 18 years or older with Medicaid and/or Medicare claims data with an International Statistical Classification of Diseases and Related Health Problems code for Down syndrome. Data were collected from January 1, 2011, to December 31, 2019, and analyzed from August 2023 to May 2024. Main Outcomes and Measures: The main outcome was prevalence of Alzheimer dementia in each calendar year and during the 9-year period. Alzheimer dementia incidence rates by calendar year and age and stratified for race or ethnicity as well as time to death after Alzheimer dementia diagnosis were also assessed. Results: There were 132 720 unique adults with Down syndrome from 2011 to 2019: 79 578 (53.2%) were male, 17 090 (11.7%) were non-Hispanic Black, 20 777 (15.7%) were Hispanic, 101 120 (68.8%) were non-Hispanic White, and 47 692 (23.3%) had ever had an Alzheimer dementia diagnosis. Incidence was 22.4 cases per 1000 person-years. The probability of an incident Alzheimer dementia diagnosis over 8 years was 0.63 (95% CI, 0.62-0.64) for those entering the study between ages 55 to 64 years. Mean (SD) age at incident diagnosis was 54.5 (7.4) years and median (IQR) age was 54.6 (9.3) years. Mean (SD) age at death among those with Alzheimer dementia was 59.2 (6.9) years (median [IQR], 59.0 [8.0] years). The mean (SD) age at onset for the Hispanic group was 54.2 (9.2) years, 52.4 (7.8) years for the American Indian or Alaska Native group, and 52.8 (8.2) years for the mixed race groups compared with 55.0 (7.8) years for the White non-Hispanic group. For age at death, there were no differences by sex. The mean (SD) age at death was later for the White non-Hispanic group (59.3 [6.8] years) compared with the Hispanic group (58.5 [7.8] years), Native American group (57.8 [7.1] years), and mixed race group (58.2 [7.0] years). Conclusions and Relevance: In this cohort study of adults with Down syndrome who were enrolled in Medicaid and Medicare, Alzheimer dementia occurred at high rates. Consistency with clinical studies of dementia in Down syndrome supports the use of administrative data in Down syndrome-Alzheimer dementia research.

Indexed as

Alzheimer DiseaseDown SyndromeAdolescentAdultAgedAged, 80 and overCohort StudiesFemaleHumansIncidenceMaleMedicaidMedicareMiddle AgedPrevalenceUnited States

Identifiers

PMID39312235
PMCPMC11420697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.